JFDA & US FDA pulls weight-loss drug off market!

January 26, 2010 in Drug Information

The Jordan Food and Drug Administration (JFDA) is pulling Reductil (chemical name Sibutramine) off the market due to a higher risk of heart complications.

I am extremely happy with this decision and I hope that all countries remove this product from their pharmacy shelves.  The FDA in the states has still not recalled this medication, but I am sure many outside groups will start putting the pressure. Reductil has already been banned across Europe following a six-year study that showed an increased risk of serious cardiovascular events in those taking Reductil compared to people not taking the drug.

Be aware that Sibutramine is also marketed under other brand names such as Meridia and Sibutrex.   JFDA also urges those taking similar products (not legally registered), such as Reduct to stop taking them for their own safety.

Another final warning, there are many different weight loss products marketed as “dietary supplements” that illegally contain undisclosed amounts of sibutramine, and similar cases pointing to Chinese “herbal supplements.”  Many of these products do not accurately list the ingredients and are not forced to meet the strict codes for medicine approval.

Sibutramine withdrawn from U.S. market

Abbott agrees to take Meridia off the market due to increased risk of heart attack and stroke.

Abbott Laboratories agreed last week to a voluntary withdrawal of Meridia (sibutramine) in the United States. The weight-loss drug has been linked to increased risk of heart attack and stroke, according to FDA.

FDA requested this withdrawal based on results from SCOUT (Sibutramine Cardiovascular Outcomes Trial), which was initiated after the European approval of the drug. Results from SCOUT indicated a 16% increase in the risk of serious heart events, including nonfatal myocardial infarction, nonfatal stroke, resuscitated cardiac arrest, and cardiovascular death, in patients given sibutramine compared with those given placebo.

“Meridia’s continued availability is not justified when you compare the very modest weight loss that people achieve on this drug to their risk of heart attack or stroke,” said John Jenkins, MD, Director of the Office of New Drugs in the FDA Center for Drug Evaluation and Research Office, in a news release. Jenkins advised physicians to stop prescribing Meridia and patient to stop taking the drug and consult with a health professional about alternative weight loss and weight loss maintenance programs.

Meridia was approved in 1997 for weight loss and maintenance of weight loss in obese people and in certain overweight people with other risks for heart disease. FDA’s decision was based on an analysis of SCOUT results during a FDA Endocrinologic and Metabolic Drugs Advisory Committee meeting on September 15.

Posted by Alex Egervary (aegervary@aphanet.org)
October 14, 2010, 5:00 pm

http://www.pharmacist.com/AM/Template.cfm?Section=Pharmacy_News&Template=/CM/ContentDisplay.cfm&ContentID=24468